mRNA Beyond COVID: Scaling Platform Technologies for Oncology
Day 1 Next-Gen Bio Stage
06/10/2026 12:25 - 12:50pm
Contributors
Monique Richards : CEO & Founder - Steel Magnolia Enterprises
The mRNA platform's success in vaccines is driving rapid expansion into oncology and immunotherapy, but manufacturing readiness for these complex applications has become the rate-limiting factor in commercialisation.
Key Discussion Points:
Platform scalability diverges sharply between high-volume vaccine production and low-volume, personalised oncology therapeutics—requiring fundamentally different manufacturing infrastructure.
Personalised and combination mRNA approaches exponentially increase manufacturing complexity—creating CDMO capacity bottlenecks and cost structures that challenge commercial viability.
Regulatory frameworks for mRNA oncology therapeutics remain in flux—creating strategic risk for companies investing in manufacturing infrastructure before pathway clarity.